[go: up one dir, main page]

TNSN97083A1 - Inhibition des matrices metalloproteases par la substitution d'acide biaryl oxobutyrique - Google Patents

Inhibition des matrices metalloproteases par la substitution d'acide biaryl oxobutyrique

Info

Publication number
TNSN97083A1
TNSN97083A1 TNTNSN97083A TNSN97083A TNSN97083A1 TN SN97083 A1 TNSN97083 A1 TN SN97083A1 TN TNSN97083 A TNTNSN97083 A TN TNSN97083A TN SN97083 A TNSN97083 A TN SN97083A TN SN97083 A1 TNSN97083 A1 TN SN97083A1
Authority
TN
Tunisia
Prior art keywords
compounds
metalloprotease
disease
conditions
matrices
Prior art date
Application number
TNTNSN97083A
Other languages
English (en)
Inventor
C Van Zandt Michael
R Britelli David
r dixon Brian
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of TNSN97083A1 publication Critical patent/TNSN97083A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/44—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/04—1,2,3-Triazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA MATRICE METALLOPROTEASE INHIBITANT LES COMPOSES, LES COMPOSITIONS PHARMACEUTIQUES ET LA METHODE DE TRAITEMENT DE LA MALADIE EN UTILISANT CES COMPOSES SONT PRESENTES. LES COMPOSES DE CETTE INVENTION ONT LES FORMULES GENERALISEES : R40 is A MONO-OU BI-HETEROCYCLIC STRUCTURE. CES COMPOSES SONT UTILES POUR INHIBITANT LES MATRICES METALLOPROTEASES ET COMBATTANT LES CONDITIONS OU MMP’S : (a) ALLEGER LES EFFETS D’OSTEOARTHRITIS. RHEUMATOID ULCERATION DE LA CORNEE, PROTEINURIA. MALADIE ANEURYSMAL AORTIQUE. EPIDERMLYSIS DISTROPHOBIQUE. BULLOSA DES CONDITIONS MENANT A DES REACTIONS INFLAMMATOIRES OSTEOPENIAS EN MEDIATION PAR L’ACTIVITE MMP. MALADIE TEMPERO MANDIBULAIRE DES JOINTS DES MALADIES DEMYELANTE DU SYSTEME NERVEUX : (b) RETARDER LA TUMEUR METASTASIS ET LA PERTE DEGENERATIVE DU CARTILAGE SUIVANT UNE BLESSURE TRAUMATIQUE DES JOINTS : (C) REDUIT LA THROMBOSIS CORONAIRE DE LA RUPTURE DE LA PLAQUE ATHROSCLEROTIQUE ; OU (e) EFFET DU CONTROLE DE LA NAISSANCE. CETTE PRESENTE INVENTION DONNE AUSSI DES COMPOSITIONS ET METHODES PHARMACEUTIQUES POUR TRAITER CES CONDITIONS .
TNTNSN97083A 1996-05-15 1997-05-09 Inhibition des matrices metalloproteases par la substitution d'acide biaryl oxobutyrique TNSN97083A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64849396A 1996-05-15 1996-05-15

Publications (1)

Publication Number Publication Date
TNSN97083A1 true TNSN97083A1 (fr) 2005-03-15

Family

ID=24601014

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN97083A TNSN97083A1 (fr) 1996-05-15 1997-05-09 Inhibition des matrices metalloproteases par la substitution d'acide biaryl oxobutyrique

Country Status (24)

Country Link
EP (1) EP0923530B1 (fr)
JP (1) JP3354942B2 (fr)
CN (1) CN1100748C (fr)
AR (1) AR007098A1 (fr)
AT (1) ATE275123T1 (fr)
AU (1) AU714207B2 (fr)
BR (1) BR9709086A (fr)
CA (1) CA2254731C (fr)
CO (1) CO5011061A1 (fr)
DE (1) DE69730508T2 (fr)
DK (1) DK0923530T3 (fr)
ES (1) ES2227696T3 (fr)
HR (1) HRP970244B1 (fr)
ID (1) ID17291A (fr)
MY (1) MY132463A (fr)
PA (1) PA8429701A1 (fr)
PE (1) PE66898A1 (fr)
PT (1) PT923530E (fr)
SV (1) SV1997000036A (fr)
TN (1) TNSN97083A1 (fr)
TW (1) TW539672B (fr)
WO (1) WO1997043239A1 (fr)
YU (1) YU18597A (fr)
ZA (1) ZA974030B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925637A (en) * 1997-05-15 1999-07-20 Bayer Corporation Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
EP1031349A1 (fr) * 1999-02-25 2000-08-30 Bayer Aktiengesellschaft Utilisation d'acides 4-biarylbutyriques et 5-biarylpentanoiques substitués pour traiter les maladies cérébrales
GB9922710D0 (en) * 1999-09-24 1999-11-24 Bayer Ag Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatatives for the treatment of multiple sclerosis
PA8539401A1 (es) * 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13
JP2004359546A (ja) * 2001-03-15 2004-12-24 Ono Pharmaceut Co Ltd ヒドロキサム酸誘導体、それらの非毒性塩およびそれらのプロドラッグ体を有効成分として含有する、固形癌の予防および／または治療剤
US20050119305A1 (en) * 2001-03-21 2005-06-02 Masao Naka Il-6 production inhibitors
KR101405823B1 (ko) * 2007-12-24 2014-06-12 주식회사 케이티앤지생명과학 녹내장의 치료 및 예방을 위한 약제 조성물
KR20090071829A (ko) * 2007-12-28 2009-07-02 주식회사 머젠스 신장질환의 치료 및 예방을 위한 약제 조성물
JP2012500260A (ja) * 2008-08-18 2012-01-05 イェール・ユニヴァーシティー Ｍｉｆモジュレーター
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
EP3126358A1 (fr) * 2014-04-03 2017-02-08 Bayer Pharma Aktiengesellschaft Acides cyclopentanecarboxyliques à disubstitution 2,5 pour traiter des maladies des voies respiratoires
WO2015150363A1 (fr) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Acides cyclopentanecarboxyliques à disubstitution 2,5 et leur utilisation
CA2944617A1 (fr) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Derives chiraux d'acide cyclopentanecarboxylique a disubstitution 2,5 et leur utilisation
CN113979992B (zh) * 2021-11-19 2022-06-24 西安欧得光电材料有限公司 一种3-取代二苯并噻吩及其合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT74511A (en) * 1994-01-22 1997-01-28 British Biotech Pharm Metalloproteinase inhibitors, pharmaceutical compns. contg. them and process to prepare the said compds.
NZ323329A (en) 1995-12-22 1999-02-25 Warner Lambert Co 4-phenyl-piperidin-1-yl butyric acid derivatives and medicaments
HRP970242A2 (en) 1996-05-15 1998-04-30 Bayer Ag Inhibition of matrix metalloproteases by 2-(omega-aroylalkyl)-4-biaryl-oxobutric acids

Also Published As

Publication number Publication date
ES2227696T3 (es) 2005-04-01
CN1225621A (zh) 1999-08-11
DK0923530T3 (da) 2005-01-03
MY132463A (en) 2007-10-31
CA2254731A1 (fr) 1997-11-20
JP3354942B2 (ja) 2002-12-09
HRP970244A2 (en) 1998-04-30
ATE275123T1 (de) 2004-09-15
TW539672B (en) 2003-07-01
HRP970244B1 (en) 2005-06-30
CA2254731C (fr) 2004-07-20
PE66898A1 (es) 1998-10-22
BR9709086A (pt) 1999-08-03
CN1100748C (zh) 2003-02-05
DE69730508T2 (de) 2005-09-29
HK1021897A1 (en) 2000-07-14
DE69730508D1 (de) 2004-10-07
JPH11510821A (ja) 1999-09-21
AU714207B2 (en) 1999-12-23
ID17291A (id) 1997-12-18
AU3122097A (en) 1997-12-05
ZA974030B (en) 1998-02-19
AR007098A1 (es) 1999-10-13
PT923530E (pt) 2004-12-31
EP0923530B1 (fr) 2004-09-01
EP0923530A1 (fr) 1999-06-23
PA8429701A1 (es) 2000-05-24
WO1997043239A1 (fr) 1997-11-20
CO5011061A1 (es) 2001-02-28
SV1997000036A (es) 1998-07-20
YU18597A (sh) 2001-12-26

Similar Documents

Publication Publication Date Title
TNSN97083A1 (fr) Inhibition des matrices metalloproteases par la substitution d'acide biaryl oxobutyrique
Moulharat et al. Effects of transforming growth factor-β on aggrecanase production and proteoglycan degradation by human chondrocytes in vitro
TNSN98019A1 (fr) Derives d'acide arylsulfonylaminohydroxamique, procede pour leur preparation et compositions pharmaceutiques les contenant.
Gepstein et al. Expression of matrix metalloproteinases in articular cartilage of temporomandibular and knee joints of mice during growth, maturation, and aging
TNSN99156A1 (fr) Derives d'acide hydroxypipecolate-hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2435471A1 (fr) Derives de dihydropyridine, procedes d'obtention et compositions pharmaceutiques en contenant
HN1997000067A (es) Acidos oxibutiricos sustituidos como inhibidores de la metaloproteasa de matriz
Churn et al. Chronic inhibition of Ca2+/calmodulin kinase II activity in the pilocarpine model of epilepsy
TNSN97084A1 (fr) Biaryl acetylenes comme inhibiteurs des matrices metalloproteinases
TNSN04191A1 (fr) Composes qui modulent l'activite de ppar et procedes pour leur preparation
IT1276783B1 (it) Formulazioni farmaceutiche e dietetiche per la profilassi e la cura di affezioni gastrointestinali
MA27570A1 (fr) 2-(1h-indazole-6-ylamino)-benzamides en tant qu'inhibiteurs de proteine-kinases, utiles pour le traitement de maladies ophtalmiques
ATE203409T1 (de) Phosphonocarboxylat-verbindungen zur behandlung abnormalen calzium- und phosphat-metabolismus
JPH11504646A (ja) 金属プロテアーゼとｔｎｆの放出を抑制するペプチド化合物およびその治療的使用
TNSN97082A1 (fr) Inhibition des matrices metalloproteases par la substitution des composes phenetyles
TNSN99013A1 (fr) Derives d'acide dihydroxyhexanoique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
UA57047C2 (uk) Заміщені похідні 4-бісфеніл-4-гідроксимасляної кислоти як інгібітори матричної металопротеази, спосіб їх одержання, фармацевтична композиція та спосіб лікування на їх основі
CA2254750A1 (fr) Inhibition de metalloproteases matricielles par des acides 2-(.omega.-aroylalkyl)-4-biaryl-4-oxobutyriques
WO1994007481A1 (fr) Derives de n-(mercaptoacyl)peptidyle utiles comme agents antidegenerescence
Graham et al. Corticosteroids repress the interleukin 1 beta-induced secretion of collagenase in human intestinal smooth muscle cells
WO1999003878A3 (fr) Nouveaux inhibiteurs des metalloproteinases, leurs emplois therapeutiques et procede de production de leur compose de depart
TNSN97085A1 (fr) Substitution oxybuterique des acides comme inhibiteurs de la matrice metalloprotease
TNSN99105A1 (fr) 2-aminopyridines contenant des substituants a noyau condenses
WO1995029689A1 (fr) Derives de n-carboxyalkyle utilises comme agents antidegeneratifs
RU2118161C1 (ru) Противовоспалительное средство